News & Updates

Does radiotherapy improve survival in NSCLC patients with cachexia?
Does radiotherapy improve survival in NSCLC patients with cachexia?
06 Feb 2024

Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.

Does radiotherapy improve survival in NSCLC patients with cachexia?
06 Feb 2024
Mixed nuts improve brain insulin action in overweight/obese older adults
Mixed nuts improve brain insulin action in overweight/obese older adults
06 Feb 2024 byStephen Padilla

Older adults with overweight or obesity who regularly eat mixed nuts appear to have better brain insulin action in the occipital and frontal regions, which are involved in the modulation of metabolic and cognitive processes, reports a study. They also show improvements in intrahepatic lipid content and different cardiometabolic risk markers but not in peripheral insulin sensitivity.

Mixed nuts improve brain insulin action in overweight/obese older adults
06 Feb 2024
Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural d
Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?
06 Feb 2024 bySarah Cheung

In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?
06 Feb 2024
Sacituzumab govitecan makes case as third-line therapy in mTNBC
Sacituzumab govitecan makes case as third-line therapy in mTNBC
05 Feb 2024